Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
What to Know About Journavx, the Non-Opioid Pain Medication Just Approved by the FDA
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex Pharmaceuticals. The drug, which is called suzetrigine and will be sold under the brand name Journavx,
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
Newly approved painkiller Journavx is 'potentially groundbreaking'
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to local medical professionals. “I think it could be a potentially groundbreaking medication,
FDA approves new, non-opioid painkiller Journavx
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.
New pain drug, Vertex’s Journavx, gets FDA approval as safer alternative to addictive opioids
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, surgeries, and other injuries and procedures.
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential'
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which she says she experienced when taking opioids.
FDA approves opioid-free pain medication with 'no sign of addiction'
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients. Doctors share what patients should know about the drug.
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves from sending pain signals to the brain.
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.
1d
Experts: Journavx a prescription to stem Long Island's addiction crisis
Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
4d
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
StudyFinds on MSN
2d
Journavx: What to know about new FDA-approved non-opioid pain medication
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
5d
on MSN
What is Non-Opioid Pain Medication? Journavx Approved by FDA
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
2d
Vertex Pharmaceuticals: Strong Buy Rating Driven by Journavx Approval and Market Expansion Opportunities
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
FDA
Vertex Pharmaceuticals
painkiller
United States
Food and Drug Administration
Feedback